$DSGN
Design Therapeutics, Inc.

2021 Q1 Form 10-Q Financial Statement

#000156459021026062 Filed on May 10, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q1
Revenue $0.00 $142.0K
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.810M $388.0K
YoY Change 366.49%
% of Gross Profit
Research & Development $3.875M $377.0K
YoY Change 927.85%
% of Gross Profit
Depreciation & Amortization $4.000K
YoY Change
% of Gross Profit
Operating Expenses $5.680M $765.0K
YoY Change 642.48%
Operating Profit -$5.680M -$623.0K
YoY Change 811.72%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $166.0K -$40.00K
YoY Change -515.0%
Pretax Income -$5.510M -$663.0K
YoY Change 731.07%
Income Tax
% Of Pretax Income
Net Earnings -$5.514M -$663.0K
YoY Change 731.67%
Net Earnings / Revenue -466.9%
Basic Earnings Per Share
Diluted Earnings Per Share -$312.5K -$25.92K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q1 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $411.3M
YoY Change
Cash & Equivalents $400.7M $2.702M
Short-Term Investments $10.65M
Other Short-Term Assets $400.0K
YoY Change
Inventory
Prepaid Expenses $298.0K
Receivables
Other Receivables
Total Short-Term Assets $411.8M
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment $100.0K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00
YoY Change
Total Long-Term Assets $100.0K
YoY Change
TOTAL ASSETS
Total Short-Term Assets $411.8M
Total Long-Term Assets $100.0K
Total Assets $411.9M
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.033M
YoY Change
Accrued Expenses $1.673M
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.706M
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $142.0K
YoY Change
Total Long-Term Liabilities $142.0K
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $3.706M
Total Long-Term Liabilities $142.0K
Total Liabilities $3.848M
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$17.44M
YoY Change
Common Stock $425.4M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $408.0M -$4.120M
YoY Change
Total Liabilities & Shareholders Equity $411.9M
YoY Change

Cashflow Statement

Concept 2021 Q1 2020 Q1
OPERATING ACTIVITIES
Net Income -$5.514M -$663.0K
YoY Change 731.67%
Depreciation, Depletion And Amortization $4.000K
YoY Change
Cash From Operating Activities -$3.697M -$2.659M
YoY Change 39.04%
INVESTING ACTIVITIES
Capital Expenditures $33.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities $61.81M
YoY Change
Cash From Investing Activities $23.03M -$39.25M
YoY Change -158.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 379.0M 44.53M
YoY Change 751.05%
NET CHANGE
Cash From Operating Activities -3.697M -2.659M
Cash From Investing Activities 23.03M -39.25M
Cash From Financing Activities 379.0M 44.53M
Net Change In Cash 398.3M 2.625M
YoY Change 15073.87%
FREE CASH FLOW
Cash From Operating Activities -$3.697M -$2.659M
Capital Expenditures $33.00K
Free Cash Flow -$3.730M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2021Q1 dei Entity Registrant Name
EntityRegistrantName
Design Therapeutics, Inc.
CY2021Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001807120
CY2021Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2021Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2021Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2021Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
55617322
CY2021Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
CY2021Q1 dei Entity File Number
EntityFileNumber
001-40288
CY2021Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-3929248
CY2021Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
6005 Hidden Valley Road
CY2021Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 110
CY2021Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Carlsbad
CY2021Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2021Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92011
CY2021Q1 dei City Area Code
CityAreaCode
858
CY2021Q1 dei Local Phone Number
LocalPhoneNumber
293-4900
CY2021Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2021Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2379000
CY2021Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
10646000
CY2020Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
33712000
CY2021Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q1 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:GrantMember
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
400693000
CY2021Q1 us-gaap Liabilities Current
LiabilitiesCurrent
3706000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-11315000
CY2021Q1 dsgn Prepaid Expense And Other Current Assets Related Party Current
PrepaidExpenseAndOtherCurrentAssetsRelatedPartyCurrent
60000
CY2020Q4 dsgn Prepaid Expense And Other Current Assets Related Party Current
PrepaidExpenseAndOtherCurrentAssetsRelatedPartyCurrent
0
CY2021Q1 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:GrantMember
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3875000
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
377000
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1805000
CY2020Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
388000
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
5680000
CY2020Q1 us-gaap Operating Expenses
OperatingExpenses
765000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-5680000
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-623000
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
166000
CY2020Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-40000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-5514000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-663000
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.31
CY2021Q1 dei Document Type
DocumentType
10-Q
CY2021Q1 dei Amendment Flag
AmendmentFlag
false
CY2021Q1 dei Document Period End Date
DocumentPeriodEndDate
2021-03-31
CY2021Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
415000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
142000
CY2021Q1 us-gaap Assets Current
AssetsCurrent
411754000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
36233000
CY2021Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
100000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
71000
CY2020Q4 us-gaap Deferred Costs
DeferredCosts
212000
CY2021Q1 us-gaap Assets
Assets
411854000
CY2020Q4 us-gaap Assets
Assets
36516000
CY2021Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
2033000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1399000
CY2021Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1673000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
931000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2330000
CY2021Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
142000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
145000
CY2021Q1 us-gaap Liabilities
Liabilities
3848000
CY2020Q4 us-gaap Liabilities
Liabilities
2475000
CY2020Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
45356000
CY2021Q1 us-gaap Common Stock Value
CommonStockValue
6000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2021Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
425435000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
451000
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-17437000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-11923000
CY2021Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
2000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
156000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
408006000
CY2021Q1 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
20000
CY2020Q4 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
20000
CY2021Q1 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2021Q1 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
0
CY2020Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
22500000
CY2021Q1 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0
CY2020Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
22012499
CY2021Q1 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2020Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
22012499
CY2021Q1 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
0
CY2020Q4 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
45625000
CY2021Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000
CY2021Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
55617322
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
16604774
CY2021Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
55042550
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15957821
CY2021Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
411854000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
36516000
CY2020Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
142000
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.04
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
17630178
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
44531000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
398314000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2625000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-4120000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-5514000
CY2020Q1 us-gaap Profit Loss
ProfitLoss
-663000
CY2021Q1 us-gaap Depreciation
Depreciation
4000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
647000
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
4000
CY2021Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
150000
CY2020Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-2000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2379000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
77000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
400693000
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
15667115
CY2021Q1 dsgn Research And Development Expenses Related Party Amount
ResearchAndDevelopmentExpensesRelatedPartyAmount
45000
CY2020Q1 dsgn Research And Development Expenses Related Party Amount
ResearchAndDevelopmentExpensesRelatedPartyAmount
8000
CY2021Q1 dsgn General And Administrative Expenses Related Party Amount
GeneralAndAdministrativeExpensesRelatedPartyAmount
60000
CY2020Q1 dsgn General And Administrative Expenses Related Party Amount
GeneralAndAdministrativeExpensesRelatedPartyAmount
112000
CY2021Q1 dsgn Other Expense Income Net Related Party Expense Amount
OtherExpenseIncomeNetRelatedPartyExpenseAmount
0
CY2020Q1 dsgn Other Expense Income Net Related Party Expense Amount
OtherExpenseIncomeNetRelatedPartyExpenseAmount
30000
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-154000
CY2020Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
181000
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5668000
CY2020Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-482000
CY2021Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
170068000
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
254271000
CY2021Q1 dsgn Stock Issued During Period Value Stock Options Exercised And Vesting Of Early Exercised Common Stock Options
StockIssuedDuringPeriodValueStockOptionsExercisedAndVestingOfEarlyExercisedCommonStockOptions
3000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
647000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-3642000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4000
CY2020Q1 us-gaap Paid In Kind Interest
PaidInKindInterest
12000
CY2020Q1 dsgn Paid In Kind Interest Related Party
PaidInKindInterestRelatedParty
26000
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
6000
CY2021Q1 dsgn Increase Decrease In Prepaid Expense And Other Assets Related Party
IncreaseDecreaseInPrepaidExpenseAndOtherAssetsRelatedParty
60000
CY2020Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-142000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1376000
CY2020Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-354000
CY2020Q1 dsgn Increase Decrease In Accounts Payable And Accrued Liabilities Related Parties
IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedParties
-1838000
CY2020Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
300000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3697000
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2659000
CY2021Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
5111000
CY2020Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
39247000
CY2021Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
28172000
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
33000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
23028000
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-39247000
CY2021Q1 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
254271000
CY2021Q1 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
124712000
CY2020Q1 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
44731000
CY2020Q1 dsgn Proceeds From Notes Payable Related Party
ProceedsFromNotesPayableRelatedParty
200000
CY2020Q1 dsgn Repayments Of Notes Payable Related Party
RepaymentsOfNotesPayableRelatedParty
400000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
378983000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2702000
CY2020Q1 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
271000
CY2020Q1 dsgn Conversion Of Stock Amount Converted Related Party
ConversionOfStockAmountConvertedRelatedParty
354000
CY2020Q1 us-gaap Interest Paid Net
InterestPaidNet
18000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
565000
CY2021Q1 us-gaap Nature Of Operations
NatureOfOperations
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1. Organization</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Design Therapeutics, Inc. (the &#8220;Company&#8221;) was incorporated in Delaware in December 2017 and is based in Carlsbad, California. The Company is a biopharmaceutical company pioneering a novel class of disease-modifying small-molecule therapeutics, called gene targeted chimeras (&#8220;GeneTACs&#8221;), that are designed to target the underlying cause of inherited nucleotide repeat expansion diseases. The Company&#8217;s lead product candidate is in Friedreich ataxia (&#8220;FA&#8221;), its second GeneTAC&#8482; program is in myotonic dystrophy type-1 (&#8220;DM1&#8221;), and it is also advancing its GeneTAC portfolio to address other serious nucleotide repeat-driven monogenic diseases.</font></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has experienced net losses and negative cash flows from operating activities since inception and expects to incur net losses for the foreseeable future as it advances its research and development programs, conducts clinical trials for any future product candidates and commercializes any such product candidates for which it receives regulatory approval. As the Company continues to incur losses, its transition to profitability will depend on the successful development, approval and commercialization of its future product candidates, and on the achievement of sufficient revenue to support its cost structure. The Company may never achieve profitability, and unless and until it does, it will need to continue to raise additional capital to fund its operations. </p>
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
4696000
CY2021Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
76000
CY2020Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
12000
CY2020Q4 dsgn Unvested Stock Liability
UnvestedStockLiability
145000
CY2021Q1 us-gaap Stockholders Equity Note Stock Split
StockholdersEquityNoteStockSplit
5-for-1
CY2021Q1 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-1.63
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
647000
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4000
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2604000
CY2020Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14511000
CY2021Q1 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
404145000
CY2020Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
35812000
CY2021Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
10644000
CY2021Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
3000
CY2021Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1000
CY2021Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
10646000
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
33556000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
156000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
33712000
CY2021Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
1
CY2020Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
0
CY2021Q1 dsgn Number Of Domestic Certificates Of Deposit Held
NumberOfDomesticCertificatesOfDepositHeld
3
CY2021Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
298000
CY2020Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
60000
CY2021Q1 us-gaap Deposits Assets Current
DepositsAssetsCurrent
90000
CY2020Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
47000
CY2021Q1 us-gaap Interest Receivable Current
InterestReceivableCurrent
27000
CY2020Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
10000
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
25000
CY2021Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
109000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
76000
CY2021Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
9000
CY2021Q1 dsgn Unvested Stock Liability Vested Shares Value
UnvestedStockLiabilityVestedSharesValue
3000
CY2021Q1 dsgn Unvested Stock Liability
UnvestedStockLiability
142000
CY2021Q1 dsgn Accrued Offering Costs
AccruedOfferingCosts
276000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5000
CY2021Q1 dsgn Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
797000
CY2020Q4 dsgn Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
266000
CY2021Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
409000
CY2021Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
191000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
100000
CY2019Q1 us-gaap Convertible Debt
ConvertibleDebt
200000
CY2021Q1 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.08
CY2018Q3 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.08
CY2019Q1 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.08
CY2021Q1 dsgn Percentage Of Selling Price Per Share That Can Convertible Into Equity Securities Sold
PercentageOfSellingPricePerShareThatCanConvertibleIntoEquitySecuritiesSold
0.80
CY2018Q3 dsgn Percentage Of Selling Price Per Share That Can Convertible Into Equity Securities Sold
PercentageOfSellingPricePerShareThatCanConvertibleIntoEquitySecuritiesSold
0.80
CY2019Q1 dsgn Percentage Of Selling Price Per Share That Can Convertible Into Equity Securities Sold
PercentageOfSellingPricePerShareThatCanConvertibleIntoEquitySecuritiesSold
0.80
CY2020Q1 us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
500000
CY2021Q1 dsgn Percentage Of Annual Rent Increase In Lease
PercentageOfAnnualRentIncreaseInLease
0.03
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
242000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
733000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
755000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
778000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
801000
CY2021Q1 dsgn Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
1387000

Files In Submission

Name View Source Status
0001564590-21-026062-index-headers.html Edgar Link pending
0001564590-21-026062-index.html Edgar Link pending
0001564590-21-026062.txt Edgar Link pending
0001564590-21-026062-xbrl.zip Edgar Link pending
dsgn-10q_20210331.htm Edgar Link pending
dsgn-20210331.xml Edgar Link completed
dsgn-20210331.xsd Edgar Link pending
dsgn-20210331_cal.xml Edgar Link unprocessable
dsgn-20210331_def.xml Edgar Link unprocessable
dsgn-20210331_lab.xml Edgar Link unprocessable
dsgn-20210331_pre.xml Edgar Link unprocessable
dsgn-ex311_8.htm Edgar Link pending
dsgn-ex321_7.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending